# Phase I Study of HRS-3005 in B-cell Malignancies

> **NCT07556822** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 190 (estimated)

## Conditions studied

- B-cell Malignancy

## Interventions

- **DRUG:** HRS-3005

## Key facts

- **NCT ID:** NCT07556822
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-10
- **Final completion:** 2028-12
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07556822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07556822, "Phase I Study of HRS-3005 in B-cell Malignancies". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07556822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*